The FDA has announced plans to introduce a pilot program designed to speed up the early stages of clinical trials for new drugs.
This initiative reflects a broader goal of federal health officials to enhance the drug development timeline and efficiency.
By accelerating these trials, the FDA aims to bolster the United States' position in the global pharmaceutical landscape, particularly in relation to competition with China.